Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

被引：0

作者：

Atefeh Zandifar

Maryam Panahi

Rahim Badrfam

Mostafa Qorbani

机构：

[1] Alborz University of Medical Sciences,Social Determinants of Health Research Center

[2] Imam Hossein Hospital,Department of Psychiatry

[3] Alborz University of Medical Sciences,Faculty of Medicine

[4] Alborz University of Medical Sciences,Non

[5] Alborz University of Medical Sciences,communicable Diseases Research Center

[6] Tehran University of Medical Sciences,Chronic Diseases Research Center, Endocrinology and Metabolism Research Institute

来源：

BMC Psychiatry | / 24卷

关键词：

Empagliflozin; Citalopram; Major depressive disorder; Neuromodulating; Anti-inflammatory;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial
Guimaraes, Mara C.
Guimaraes, Tiago M.
Hallak, Jaime E.
Abrao, Joao
Machado-de-Sousa, Joao P.
BRAZILIAN JOURNAL OF PSYCHIATRY, 2021, 43 (05) : 484 - 493
[42] Efficacy of spironolactone as adjunctive therapy to sodium valproate in bipolar-I disorder: A double-blind, randomized, placebo-controlled clinical trial
Zandifar, Atefeh
Badrfam, Rahim
Gholamian, Fatemeh
Shafiee, Arman
BRAIN AND BEHAVIOR, 2023, 13 (12):
[43] Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
Mathews, Maju
Gommoll, Carl
Chen, Dalei
Nunez, Rene
Khan, Arif
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (02) : 67 - 74
[44] Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial
Kato, Masaki
Nakagome, Kazuyuki
Baba, Takamichi
Sonoyama, Takuhiro
Okutsu, Daiki
Yamanaka, Hideki
Shimizu, Ryosuke
Motomiya, Tomoko
Inoue, Takeshi
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2023, 77 (09) : 497 - 509
[45] Efficacy and Safety of Adjunctive Armodafinil in Adults With Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Calabrese, Joseph R.
Frye, Mark A.
Yang, Ronghua
Ketter, Terence A.
JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (10) : 1054 - +
[46] Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial
Salardini, Elaheh
Zeinoddini, Atefeh
Mohammadinejad, Payam
Khodaie-Ardakani, Mohammad-Reza
Zahraei, Nagmeh
Zeinoddini, Arefeh
Akhondzadeh, Shahin
JOURNAL OF PSYCHIATRIC RESEARCH, 2016, 75 : 24 - 30
[47] Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial
Akkasheh, Ghodarz
Kashani-Poor, Zahra
Tajabadi-Ebrahimi, Maryam
Jafari, Parvaneh
Akbari, Hossein
Taghizadeh, Mohsen
Memarzadeh, Mohammad Reza
Asemi, Zatollah
Esmaillzadeh, Ahmad
NUTRITION, 2016, 32 (03) : 315 - 320
[48] A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder
Liebowitz, Michael R.
Yeung, Paul P.
Entsuah, Richard
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (11) : 1663 - 1672
[49] L-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial
Shamabadi, Ahmad
Kafi, Farnaz
Bafrani, Melika Arab
Asadigandomani, Hassan
Basti, Fatemeh A.
Akhondzadeh, Shahin
JOURNAL OF AFFECTIVE DISORDERS, 2023, 333 : 38 - 43
[50] Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial
Dehbozorghi, Sara
Bagheri, Sayna
Moradi, Kamyar
Shokraee, Kamyar
Mohammadi, Mohammad-Reza
Akhondzadeh, Shahin
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2019, 73 (11) : 690 - 696

← 1 2 3 4 5 →